Longevity senotherapeutics report: Oisín Biotechnologies

Latest articles

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

New webinar will explore the opportunity of ovarian longevity

What does delaying menopause mean in terms of investment activity, societal change and the technologies that will reshape the lives of multiple millions of...

Most read

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Editor's picks

Exclusive: “Mitlets” hold potential for mitochondria transfusion

Mitrix Bio believes recently discovered blood components may support transfusion of large quantities of healthy mitochondria from donor to patient. Earlier this year, we brought...

Optimise your body and mind by tackling cell stress

Want to live longer and heathier? Combating cell stress is an important first step on your longevity journey. It's a fast-paced, busy world, and we're...

Crypto – pulling a (Moon) Rabbit out a hat for longevity

Angel Versetti on why it makes sense to look at more experimental solutions for longevity. Earlier this week we brought you part one of our...

Click the globe for translations.

Leveraging technology and information to address the damage created by the aging process itself.

Over the coming weeks, we will be bringing you extracts from 7 company profiles from our Longevity Senotherapeutics Report. Each profile includes an assessment of Longevity Potential, Pre-Clinical and Clinical Studies, Technology/platform analysis, Safety and Risks, Target Market and Success Factors.

We also study each company’s IP, team, UVP, product efficacy, competitive advantage, runway and inflection point, and much more. Here’s the lowdown on Oisín.

To view a full size version of Oisín’s profile please click here.

Oisín-Profile
.

Founded in 2014, Oisín Biotechnologies is a platform drug development company that had an initial goal of producing a senolytic platform that could kill senescent cells without using toxic drugs and causing significant collateral damage. Most senolytics are repurposed chemotherapeutics that kill cells rather indiscriminately based on certain metabolic characteristics. “The challenge in the field is to develop drugs that selectively kill aberrant cells without causing unacceptable harm to the patient.” Oisín’s lodestar is that the essence of life is information – chemistry is just a substrate.

“For the bulk of human history we have treated illness with plants and prayers, small molecule drugs and rituals. It is only relatively recently that science and medicine have really endeavoured to treat diseases by manipulating information in life, and the results have already been astounding. In the case of senolytics, using genetic approaches to take targeting out of the realm of chemistry and into the realm of information allows for a degree of selectivity that has thus far been impossible.”

Oisin

Oisín seeks to demonstrate that the solution to mitigating the effects of age-related diseases is to address the damage created by the aging process itself. To accomplish this, Oisín is building genetic medicines to treat diseases of old age via their underlying causes. “Our approach is based on the notion that senescent cells “know” they are senescent, they are transcriptionally aberrant, and we can exploit this to selectively kill them with what amounts to a simple computer program written in DNA.”

Its first therapeutic candidate, OB-001, is currently the only viable senolytic that can kill senescent cells based on genetic activity. OB-001 contains a non-integrating DNA plasmid that encodes a potent inducible suicide gene which targets senescent cells with elevated p16 transcriptional activity. Multiple high-profile published animal studies have shown the profound benefits of removing high p16 expressing cells, but no one has been able to eliminate these cells efficiently and selectively in humans. “Our technology effectively kills senescent cells based on what they are “thinking” or, more technically speaking, based on their transcriptional activity” says Matthew Scholz, CEO of Oisín Biotechnologies. “Our unique approach and delivery technology allows us to target multiple causes of aging in a way that would be impossible using traditional small molecule drugs.”

Oisín Biotechnologies is currently performing studies required to take their lead candidate, OB-001, into the clinic where its first application will be in kidney disease. Oisín is also developing therapeutics for targets other than p16 and senescence. These include programs in oncology, through their spinout OncoSenX, and programs in cellular reprogramming, hTERT (telomerase), cardiovascular disease, frailty, sarcopenia, fibrosis and several other targets they cannot disclose at this time. The company’s mission is to target aging broadly, and its strategy is to go after targets related to multiple hallmarks of aging. Oisín Biotechnologies is advancing some of these programs internally and partnering with academic and commercial entities for others.

Oisín Biotechnologies was started when co-founders Matthew Scholz & Gary Hudson met at a health extension salon where Judy Campisi (Founder of Unity Biotechnology) was presenting some of the early data from the Mayo Clinic’s transgenic mouse studies. Matthew was impressed by the clear benefits of eliminating senescent cells and had an idea for how to accomplish this in humans in a way that was clinically viable. Elaborating his idea to Gary at the bar after the conference, they decided that the idea had to be pursued.

Oisin

A key aspect of their strategic approach is the use of a unique non-viral delivery platform for encapsulation and systemic delivery of their genetic medicine. They employed the Entos Fusogenix, proteo-lipid vehicle (PLV) technology developed by John Lewis (now CSO of Oisín Biotechnologies). This technology allows for high efficiency delivery of their therapeutic candidate with an unparalleled toxicity profile.

Oisín’s flexible, low cost, and scalable gene delivery platform has shown promising results in preclinical testing and holds immense potential. It can quickly be adapted in response to novel R&D discoveries and can efficiently support multiple clinical pipeline applications in parallel.

Moving forward, Oisín (and its OncoSenX spinoff) is primarily focused on reaching Phase 1 & 2 clinical milestones for their lead candidates as expeditiously as possible and then broadening the label to address other senescence-mediated age-associated diseases.

Oisín Biotechnologies is already engaged in active pharma licensing discussions and their goal is to position themselves for major licensing deals and a potential IPO within the next few years. The two main components of Oisín’s proprietary platform, the PLV delivery system and highly programmable DNA payloads, synergise to address the primary challenges present in the senotherapeutics industry today.

Access to the report can be found HERE, and check out our other senotherapeutic company profiles HERE.

Images courtesy of Oisín Biotechnologies
Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

Most popular

New supplement slows aging and promotes weight loss

Sugar-proof your way to a longer life. Reducing AGEs to slow aging and increase weight loss – how one supplement is fighting the war...

An antiaging supplement that also reduces appetite?

One for the AGEs: Juvify signs IP licensing deal with Buck Institute for GLYLO antiaging supplement that aims to reduce glycation. A researcher at the...

Resveratrol – the small molecule with big antiaging ideas

When it comes to antiaging molecules, we can learn a thing or two from plants. As so often in natural world, plants have a few...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Related articles

Buck Institute awarded $12.7m to join senescence network

NIH award to join SenNet, the Cellular Senescence Network, will enable Buck scientists to identify and characterise senescent cells – recognised as a driver...

Deep learning platform seeks near-term indications of age-related diseases

Arrive co-founder talks combining aging cell biology, drug screening and deep learning technology in the quest to discover novel antiaging targets. Silicon Valley and Singapore-based...

A new approach to reversing tissue aging

Exploring Revel’s enzyme-based approach to breaking down crosslinks and targeting tissue aging. Last year, a startup called Revel Pharmaceuticals emerged from the labs at Yale...

Ovarian aging – your questions answered

Ovarian longevity and the significance of ovarian aging is poorly understood – our video aims to change that. Join our Scientific Editor Daragh Campbell as...

Learning lessons from clinical trial failure

Metabesity 2021: Joan Mannick talks longevity scientific breakthroughs, healthspan endpoints, her new role at Life Biosciences, and what can be learned from resTORbio’s clinical...